Expanding Mouse-Adapted Yamagata-like Influenza B Viruses in Eggs Enhances In Vivo Lethality in BALB/c Mice
- PMID: 35746770
- PMCID: PMC9229684
- DOI: 10.3390/v14061299
Expanding Mouse-Adapted Yamagata-like Influenza B Viruses in Eggs Enhances In Vivo Lethality in BALB/c Mice
Abstract
Despite the yearly global impact of influenza B viruses (IBVs), limited host range has been a hurdle to developing a readily accessible small animal disease model for vaccine studies. Mouse-adapting IBV can produce highly pathogenic viruses through serial lung passaging in mice. Previous studies have highlighted amino acid changes throughout the viral genome correlating with increased pathogenicity, but no consensus mutations have been determined. We aimed to show that growth system can play a role in mouse-adapted IBV lethality. Two Yamagata-lineage IBVs were serially passaged 10 times in mouse lungs before expansion in embryonated eggs or Madin-Darby canine kidney cells (London line) for use in challenge studies. We observed that virus grown in embryonated eggs was significantly more lethal in mice than the same virus grown in cell culture. Ten additional serial lung passages of one strain again showed virus grown in eggs was more lethal than virus grown in cells. Additionally, no mutations in the surface glycoprotein amino acid sequences correlated to differences in lethality. Our results suggest growth system can influence lethality of mouse-adapted IBVs after serial lung passaging. Further research can highlight improved mechanisms for developing animal disease models for IBV vaccine research.
Keywords: embryonated eggs; growth system; hemagglutinin; influenza B virus; mouse-adapting; neuraminidase.
Conflict of interest statement
The authors declare no conflict of interest.
Figures





Similar articles
-
A Single Amino Acid in the Polymerase Acidic Protein Determines the Pathogenicity of Influenza B Viruses.J Virol. 2018 Jun 13;92(13):e00259-18. doi: 10.1128/JVI.00259-18. Print 2018 Jul 1. J Virol. 2018. PMID: 29643248 Free PMC article.
-
Comparison of immunogenicity of cell-and egg-passaged viruses for manufacturing MDCK cell culture-based influenza vaccines.Virus Res. 2015 Jun 2;204:40-6. doi: 10.1016/j.virusres.2015.04.005. Epub 2015 Apr 17. Virus Res. 2015. PMID: 25892718
-
Development of high-yield influenza B virus vaccine viruses.Proc Natl Acad Sci U S A. 2016 Dec 20;113(51):E8296-E8305. doi: 10.1073/pnas.1616530113. Epub 2016 Dec 5. Proc Natl Acad Sci U S A. 2016. PMID: 27930325 Free PMC article.
-
Experimental Infection Using Mouse-Adapted Influenza B Virus in a Mouse Model.Viruses. 2020 Apr 21;12(4):470. doi: 10.3390/v12040470. Viruses. 2020. PMID: 32326238 Free PMC article.
-
Safety, Immunogenicity, and Protective Efficacy of an H5N1 Chimeric Cold-Adapted Attenuated Virus Vaccine in a Mouse Model.Viruses. 2021 Dec 3;13(12):2420. doi: 10.3390/v13122420. Viruses. 2021. PMID: 34960689 Free PMC article.
Cited by
-
A Single-Component Multilayered Self-Assembling Protein Nanoparticle Vaccine Based on Extracellular Domains of Matrix Protein 2 against Both Influenza A and B.Vaccines (Basel). 2024 Aug 28;12(9):975. doi: 10.3390/vaccines12090975. Vaccines (Basel). 2024. PMID: 39340007 Free PMC article.
-
Adenoviral-Vectored Multivalent Vaccine Provides Durable Protection Against Influenza B Viruses from Victoria-like and Yamagata-like Lineages.Int J Mol Sci. 2025 Feb 12;26(4):1538. doi: 10.3390/ijms26041538. Int J Mol Sci. 2025. PMID: 40004004 Free PMC article.
-
Impact of adjuvant: Trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus.Front Immunol. 2022 Sep 30;13:1002286. doi: 10.3389/fimmu.2022.1002286. eCollection 2022. Front Immunol. 2022. PMID: 36248851 Free PMC article.
-
Multivalent Epigraph Hemagglutinin Vaccine Protects against Influenza B Virus in Mice.Pathogens. 2024 Jan 23;13(2):97. doi: 10.3390/pathogens13020097. Pathogens. 2024. PMID: 38392835 Free PMC article.
References
-
- World Health Organization Influenza (Seasonal) [(accessed on 1 September 2021)]. Available online: https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal)
-
- Laporte M., Stevaert A., Raeymaekers V., Boogaerts T., Nehlmeier I., Chiu W., Benkheil M., Vanaudenaerde B., Pöhlmann S., Naesens L. Hemagglutinin Cleavability, Acid Stability, and Temperature Dependence Optimize Influenza B Virus for Replication in Human Airways. J. Virol. 2019;94:e01430-19. doi: 10.1128/JVI.01430-19. - DOI - PMC - PubMed
-
- Caini S., Kusznierz G., Garate V.V., Wangchuk S., Thapa B., Júnior F.J.D.P., De Almeida W.A.F., Njouom R., Fasce R.A., Bustos P., et al. The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century. PLoS ONE. 2019;14:e0222381. doi: 10.1371/journal.pone.0222381. - DOI - PMC - PubMed
-
- Chan P.K.S., Chan M.C.W., Cheung J.L.K., Lee N., Leung T.F., Yeung A.C.M., Wong M.C.S., Ngai K.L.K., Nelson E.A.S., Hui D.S.C. Influenza B Lineage Circulation and Hospitalization Rates in a Subtropical City, Hong Kong, 2000–2010. Clin. Infect. Dis. 2012;56:677–684. doi: 10.1093/cid/cis885. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical